PharmaVoice - Latest News

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

 As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.